ABBOTT-CITALOPRAM TABLET

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

Dostupné z:

ABBOTT LABORATORIES, LIMITED

ATC kód:

N06AB04

INN (Medzinárodný Name):

CITALOPRAM

Dávkovanie:

20MG

Forma lieku:

TABLET

Zloženie:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20MG

Spôsob podávania:

ORAL

Počet v balení:

100/500

Typ predpisu:

Prescription

Terapeutické oblasti:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Prehľad produktov:

Active ingredient group (AIG) number: 0136243001; AHFS:

Stav Autorizácia:

CANCELLED POST MARKET

Dátum Autorizácia:

2015-12-31

Súhrn charakteristických

_ _
_Abbott-Citalopram Product Monograph _
_Page 1 of 48_
PRODUCT MONOGRAPH
PR
ABBOTT-CITALOPRAM _ _
Citalopram Tablets USP
10 mg, 20 mg and 40 mg citalopram (as citalopram hydrobromide)
Antidepressant
BGP Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
January 7, 2015
Submission Control No.: 180716
_ _
_Abbott-Citalopram Product Monograph _
_Page 2 of 48 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND STABILITY
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
..........................................................................31
CLINICAL TRIALS
.......................................................................................